Attached files
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report of ENDRA Life Sciences Inc.
(the “Company”) on Form 10-Q for the period ended March
31, 2017 as filed with the Securities and Exchange Commission on
the date hereof (the “Report”), we, Francois Michelon,
Chief Executive Officer and Chairman of the Company, and David
Wells, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully
complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2)
The information
contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Company.
A
signed original of this written statement required by Section 906
has been provided to ENDRA Life Sciences Inc. and will be retained
by ENDRA Life Sciences Inc. and furnished to the Securities and
Exchange Commission or its staff upon request.
|
/s/
Francois Michelon
|
|
/s/
David R. Wells
|
|
Name:
Francois Michelon
|
|
Name:
David R. Wells
|
|
Title:
Chief Executive Officer and Chairman
|
|
Title:
Chief Financial Officer
|
|
Date:
June 21, 2017
|
|
Date:
June 21, 2017
|
|
|
|
|